Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.50 USD

29.50
26,896,912

+0.40 (1.37%)

Updated Jul 16, 2024 04:01 PM ET

After-Market: $29.49 -0.01 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (106 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Pfizer Leukemia Drug Meets Primary Endpoint in Phase III

Pfizer Inc. (PFE) and partner Avillion LLP announced that a phase III study (BFORE) evaluating its marketed drug Bosulif in the first-line setting met the primary endpoint

    Pfizer (PFE) Presents Favorable Data on Leukemia Candidate

    Pfizer Inc. (PFE) announced new positive data from a randomized phase II study on its investigational candidate glasdegib (PF-04449913) for the first-line treatment of patients with acute myeloid leukemia (AML).

      Merck's Keytruda Gets Priority Review for Hodgkin Lymphoma

      Merck & Co., Inc.'s (MRK) supplemental Biologics License Application (sBLA) ??? the second this week ??? for its anti-PD-1 therapy, Keytruda, has been accepted for priority review by the FDA.

        Pfizer Offers Positive Phase III Data on Pediatric Epilesy Drug

        Pfizer Inc. (PFE) announced positive top-line results from a phase III study evaluating its marketed drug, Lyrica (pregabalin), as adjunctive therapy for the treatment of pediatric patients suffering from epilepsy with partial-onset seizures.

          Tirthankar Chakraborty headshot

          5 Top Performing S&P 500 Stocks of November

          President-elect Donald Trump has proposed a raft of fiscal-stimulus measures, which has pushed the S&P 500 to almost an all-time high in November

            Pfizer's Herceptin Biosimilar Meets Primary Endpoint in Study

            Pfizer, Inc. (PFE) recently announced that its experimental biosimilar of Roche Holding AG's (RHHBY) breast cancer drug - Herceptin - has reached the primary endpoint in a pivotal study.

              ARIAD's Leukemia Drug Iclusig Gets Full Approval in U.S.

              ARIAD Pharmaceuticals, Inc. (ARIA) announced that the FDA has granted a full approval to its leukemia drug, Iclusig (ponatinib), following its successful completion of the commitments made on accelerated approval in Dec 2012.

                Pfizer/Merck KGaA: Priority Review for Cancer Drug Avelumab

                Pfizer, Inc. (PFE) and German partner Merck KGaA (MKGAF) announced that the Biologics License Application for avelumab, has been accepted for priority review by the FDA.

                  J&J (JNJ) Stands Tall in 2016: Reasons for Outperformance

                  Johnson & Johnson's (JNJ) share price is up 9.5% in the year-to-date period. This compares favorably with the 8.0% fall for the Zacks classified Large-Cap Pharma industry.

                    The Zacks Analyst Blog Highlights: Pfizer, Microsoft, Priceline, Expedia and United Continental

                    The Zacks Analyst Blog Highlights: Pfizer, Microsoft, Priceline, Expedia and United Continental

                      Stock Market News for November 21, 2016

                      Rising rate hike possibilities boosted the dollar to its best settlement in 13 years, which in turn dragged the benchmarks into the red on Friday.

                        Stock Market News for November 08, 2016

                        Benchmarks ended higher on Monday after the FBI said that it would not press criminal charges against Democratic nominee Hillary Clinton

                          The Zacks Analyst Blog Highlights: Allergan, Gilead Sciences, Pfizer, Regeneron Pharmaceuticals and Lion Biotechnologies

                          The Zacks Analyst Blog Highlights: Allergan, Gilead Sciences, Pfizer, Regeneron Pharmaceuticals and Lion Biotechnologies

                            Mark Vickery headshot

                            Fed Meets, Q3 Earnings Continue, Election Uncertainty Rules

                            With the omnipresent General Election looming, little else matters to investors at this point.

                              Stock Market News for October 19, 2016

                              Upbeat earnings results led the benchmarks to close in the green on Tuesday

                                Mark Vickery headshot

                                Market News Over Summer Vacation: PFE, AZN, TSLA, LZB

                                You know you're in a slow news cycle when the market focus is on a Janet Yellen speech that doesn't happen until Friday, and no one expects any action to come of it anyway.

                                  Mark Vickery headshot

                                  M&A Boosts Intersil, Syngenta and Medivation in Pre-Market

                                  We???re seeing big gains among smaller companies ready to be purchased by much bigger fish: PFE, MDVN, SYT, ISIL.

                                    Sheraz Mian headshot

                                    New Research Reports for Pfizer, Cisco & Visa

                                    Today's must-read reports are for Pfizer (PFE), Cisco (CSCO) and Visa (V).

                                      Mark Vickery headshot

                                      Q2 Earnings Reports Come in Mixed, Futures Down Slightly

                                      Q2 earnings season may have passed the midway point last week, but plenty of important companies are reporting earnings this morning: PFE, PG, MNT, CVS, SODA and RCL.

                                        John Blank headshot

                                        Don't Make It Complicated, Own Drug Stocks

                                        The basic ingredients for rising drug demand -- the frailties that accompany aging -- are going to be there for the next 2 decades, in the USA and elsewhere.

                                          Neena Mishra headshot

                                          Bull of the Day: Pfizer (PFE)

                                          Bet on this big pharma stock for growth, stability and income.

                                            Kevin Cook headshot

                                            Bear of the Day: AbbVie (ABBV)

                                            Estimates were already sliding before the Feds took up the patent fight by "hopeful rival" Coherus

                                              Stock Market News for May 04, 2016

                                                Stock Market News for April 07, 2016

                                                Benchmarks closed in the green on Wednesday following gains in biotech and energy stocks

                                                  Stock Market News for March 22, 2012

                                                  Gains in healthcare and telecom stocks helped the benchmarks end marginally higher on Monday.